Table 1
Key results of randomized controlled trials evaluating targeted medical therapy for chronic thromboembolic pulmonary hypertension. Data presented as indicated value or mean (+/–) standard deviation.9,10,11,12 6MWD: 6-minute walking distance; PVR: pulmonary vascular resistance
| TRIAL | DRUG | RESULTS POSTED | SUBJECTS (N) | 6MWD (M) | 6MWD (EFFECT M) | PVR BASELINE (DYN·S/CM5) | PVR EFFECT (%) |
|---|---|---|---|---|---|---|---|
| CTREPH | Treprostinil | 2019 | 105 | 308 ± 68β | +45#, β | 845 ± 386β | –25 |
| MERIT-1 | Macitentan | 2018 | 80 | 352 ± 81 | +34# | 957 ± 435 | –16 |
| CHEST-1 | Riociguat | 2014 | 261 | 347 ± 80 | +46 | 787 ± 422 | –31 |
| BENEFIT | Bosentan | 2007 | 157 | 342 ± 84 | +2** | 783 (95% CI 703–861) | –24 |
[i] **: Not statistically significant; #: assessed at 24 weeks; β: high-dose treprostinil arm